{"id":"revefenacin-175-g-formoterol-20-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Dry mouth"}]},"_chembl":{"chemblId":"CHEMBL3833319","moleculeType":"Small molecule","molecularWeight":"597.76"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Revefenacin blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. Formoterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and causing smooth muscle relaxation. The combination provides dual bronchodilation through complementary mechanisms.","oneSentence":"Revefenacin is a long-acting muscarinic antagonist that relaxes airway smooth muscle, while formoterol is a long-acting beta-2 agonist that further dilates airways, together providing bronchodilation for chronic obstructive pulmonary disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:47.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yupelri","Perforomist"],"phase":"marketed","status":"active","brandName":"Revefenacin 175 µg, Formoterol 20 µg","genericName":"Revefenacin 175 µg, Formoterol 20 µg","companyName":"University of Tennessee Graduate School of Medicine","companyId":"university-of-tennessee-graduate-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Revefenacin is a long-acting muscarinic antagonist that relaxes airway smooth muscle, while formoterol is a long-acting beta-2 agonist that further dilates airways, together providing bronchodilation for chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}